Brian Frederick

Protagonist Therapeutics
Milpitas, CA
USA Papers:
T.55 Preclinical Characterization of PTG-100, an Oral α4β7 Integrin Peptide Antagonist for Ulcerative Colitis
T.103 Discovery and Characterization of Novel, Oral Peptide Antagonists of Human IL-23 Receptor That Are Efficacious in a Rat Model of IBD